With the increasing use of gonadotropin releasing hormone antagonist protocols, it has become an option to trigger ovulation with gonadotropin releasing hormone agonist which has several advantages over human chorionic gonadotropin triggering; among those an elimination or reduction in ovarian hyperstimulation syndrome, and a reduction in luteal phase discomfort. Thus, this paper questions the ...

of GnRH receptor and gonadotropin subunit gene expression were measured by quantitative PCR.­ Levels of gene expression for the GnRH receptor and gonadotropin subunits decreased following treatment with the GnRH antagonist in pituitaries of gilts from the Index and Control lines; however, these values remained unchanged in pituitar-ies from Meish­an gilts. Identification of unique genetic chang...

GnRH antagonists have been used with increasing frequency in assisted reproduction treatments over the past few years and have been associated with quicker and more profound LH suppression and shorter treatment cycles than conventional GnRH agonists. Usually, these are commenced on day 6 of FSH stimulation without allowing for patient variation in response to treatment. The study was aimed at i...

this study explored the effects of gnrh agonist (gnrha) immunity on expression of fshr mrna in pituitary and fshr protein in uteri, and also confirmed its efficacy on uterine development. 42 prepuberty and non cyclic ewes were assigned to 6 experimental groups (eg) during anestrus season. animals in eg-i, eg-ii and eg-iii were subcutaneously injected with 200, 300 and 400 μg alarelin antigens (...

An unusual prostate-specific antigen (PSA) decrease in a Japanese patient with advanced castration-resistant prostate cancer (CRPC) treated with luteinizing hormone-releasing hormone (LH-RH) antagonist after cerebral bleeding was presented. There have been no previous reports that cerebral bleeding or trepanation/drainage of hematoma decreased PSA level, which would make this the first. The LH-...